Sohini Das

All stories by Sohini Das

Low turnout forces govt to mull private rollout of Covid vaccine

Low turnout forces govt to mull private rollout of Covid vaccine

Rediff.com10 Feb 2021

Two weeks after the vaccination programme started, about 37 per cent of the targeted 10 million healthcare professionals had received the first shot. This slow rate may prompt the government to allow vaccines in the private market sooner, to use up the doses before they expire, Sohini Das reports.

Lupin aims to enter Chinese market in the next one year

Lupin aims to enter Chinese market in the next one year

Rediff.com8 Feb 2021

Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.

More Covid vaccine candidates get approval for clinical trials in India

More Covid vaccine candidates get approval for clinical trials in India

Rediff.com6 Feb 2021

Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.

More Indians will take vaccine if politicians do: Survey

More Indians will take vaccine if politicians do: Survey

Rediff.com5 Feb 2021

In India, Opposition parties along with healthcare professionals have urged the government, including Prime Minister Narendra Modi and top leaders, to take either of the Covishield or Covaxin doses, which could help in drastically reducing trust and fear issues amongst citizens., reports Sohini Das.

Why early applicant Pfizer's Covid vaccine is delayed

Why early applicant Pfizer's Covid vaccine is delayed

Rediff.com19 Jan 2021

Pfizer sought to participate in the Subject Expert Committee consultations towards an emergency use authorisation for its Covid-19 vaccine. However, the company representatives have been unable to participate in the meetings because of extremely short notices of a few hours or less and time-zone limitations.

Serum Institute may supply 400 million doses to Gavi-Covax

Serum Institute may supply 400 million doses to Gavi-Covax

Rediff.com19 Jan 2021

Serum Institute already has two deals of 100 million each to supply the Oxford-AstraZeneca and the Novavax vaccine to Gavi-Covax at $3 per dose.

V G Somani: The head of DCGI known as man of actions, not of words

V G Somani: The head of DCGI known as man of actions, not of words

Rediff.com18 Jan 2021

'Safety is my first priority.' 'I need to ensure that any drug or vaccine that our citizens get is first safe.'

Serum Institute began its journey in a small lab in stud farm

Serum Institute began its journey in a small lab in stud farm

Rediff.com16 Jan 2021

The Covishield maker's forte throughout the past half a century has been a combination of affordable vaccines and high volumes. Its tetanus, diphtheria and measles vaccines are known throughout the world, reports Sohini Das.

'It'll take 3-4 years to vaccinate 80% of population'

'It'll take 3-4 years to vaccinate 80% of population'

Rediff.com11 Jan 2021

'We are hoping by March, the government allows us to export and give it to the private market.'

Kids will have to wait for a COVID-19 vaccine

Kids will have to wait for a COVID-19 vaccine

Rediff.com28 Dec 2020

The primary objective was to get the adult vaccine as children rarely have a severe form of the disease. Once schools reopen, the demand for vaccines for children under 12 may soar.

Vaccine will be available to all

Vaccine will be available to all

Rediff.com17 Dec 2020

The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.

 Covaxin shows robust response

Covaxin shows robust response

Rediff.com17 Dec 2020

Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.

COVID-19 vaccines likely to have longer shelf life

COVID-19 vaccines likely to have longer shelf life

Rediff.com14 Dec 2020

A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.

Is this Indian Covid vaccine better than Pfizer's?

Is this Indian Covid vaccine better than Pfizer's?

Rediff.com12 Dec 2020

India's first mRNA platform-based vaccine will remain stable at 2-8 degrees Celsius while Pfizer-BioNTech's vaccine needs minus 70 degrees Celsius and Moderna vaccine can remain stable for six months at minus 20 degrees Celsius, reports Sohini Das.

Covishield volunteer decides to move court against Serum Institute

Covishield volunteer decides to move court against Serum Institute

Rediff.com11 Dec 2020

'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.

Serum Institute set to sign deal with Centre for Covishield

Serum Institute set to sign deal with Centre for Covishield

Rediff.com9 Dec 2020

By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.

How Indian pharma bounced back from lockdown lows

How Indian pharma bounced back from lockdown lows

Rediff.com7 Dec 2020

From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Next